- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03653754
Growth and Body Composition in Children
June 20, 2019 updated by: Bo Young Hong, The Catholic University of Korea
Growth and Body Composition in Children With Disabilities and Typically Developing Children
This study is planned to measure and compare body composition indexes and growth between typically developing children and those with disabilities in South Korea for understanding the nutritional and growth status.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Inclusion criteria for typically developing children
- typically developing children in 5th and 6th grades of elementary schools
- children whose parents checked the agreement form distributed by schools
Inclusion criteria for children with disabilities
- children and adolescent who are in special schools
- children whose parents checked the agreement form distributed by schools
- children who were able to cooperate during the body composition analysis
Exclusion criteria for both groups
- those whom do not have written informed consent
- who are not able to stay calmly during the body composition analysis
- All measurements done at two elementary schools on the day of the annual physical examination
- Measurement of height and body weight for growth
- Measurement of body composition index: Inbody 770 and Inbody S10, body composition analyzers
Study Type
Observational
Enrollment (Actual)
428
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Suwon-si, Korea, Republic of
- St. Vincent's Hospital, The Catholic University of Korea
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
- Typically developing children who are in the 5th and 6th grades of elementary schools
- Children with neurodevelopmental disabilities in a special school
Description
Inclusion Criteria:
- Those who agreed to participate both parents and a child
- Typically developing children: among the 5th and 6th grade of two elementary schools.
- Children with neurodevelopmental disabilities: among the students in a special school.
Exclusion Criteria:
- Who do not want to participate
- Who are not possible to do the Inbody examination
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
typically developing
Intervention: Measurement of growth and body composition.
Growth (height, body weight), and body composition was measured at school.
|
Growth (height and body weight), and body composition were measured.
For the body composition, Inbody 770 and Inbody S10 were used.
Other Names:
|
neurodisabilities
Intervention: Measurement of growth and body composition.
Growth (height, body weight), and body composition was measured at school.
|
Growth (height and body weight), and body composition were measured.
For the body composition, Inbody 770 and Inbody S10 were used.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BW
Time Frame: through study completion, an average of 1.5 month
|
body weight (kg)
|
through study completion, an average of 1.5 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
skeletal muscle mass (kg)
Time Frame: through study completion, an average of 1.5 month
|
skeletal muscle mass measured by body composition analyzers (Inbody 770 and Inbody S10)
|
through study completion, an average of 1.5 month
|
fat mass (kg)
Time Frame: through study completion, an average of 1.5 month
|
fat mass measured by body composition analyzers (Inbody 770 and Inbody S10)
|
through study completion, an average of 1.5 month
|
height
Time Frame: through study completion, an average of 1.5 month
|
height
|
through study completion, an average of 1.5 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bo Young Hong, MD, PhD, St. Vincent's Hospital, The Catholic University of Korea
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 16, 2018
Primary Completion (Actual)
June 30, 2018
Study Completion (Actual)
November 29, 2018
Study Registration Dates
First Submitted
July 24, 2018
First Submitted That Met QC Criteria
August 29, 2018
First Posted (Actual)
August 31, 2018
Study Record Updates
Last Update Posted (Actual)
June 24, 2019
Last Update Submitted That Met QC Criteria
June 20, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VC17ONSI0200
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth
-
University of California, DavisCompletedGrowth Acceleration | Growth RetardationUnited States
-
Northwell HealthRecruitingGrowth | Growth Disorders | Growth Failure | Growth Hormone TreatmentUnited States
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in ChildrenIsrael, Denmark, Belgium, Spain, Macedonia, The Former Yugoslav Republic of, Turkey, United Kingdom, France, Slovenia, Czech Republic
-
Novo Nordisk A/SWithdrawnGrowth Hormone Disorder | Growth Hormone Deficiency in Children
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyFrance
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone Disorder | Adult Growth Hormone DeficiencyUnited States
-
University of CopenhagenUniversity of Aarhus; Arla FoodsCompletedGrowth Acceleration | Growth; Stunting, NutritionalDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
Clinical Trials on Measurement of growth and body composition
-
Centre Jean PerrinCompletedBreast Cancer | Hormonal TherapyFrance
-
Prof. Claude PichardCompletedBody CompositionSwitzerland
-
Kaohsiung Veterans General Hospital.Recruiting
-
Vrije Universiteit BrusselKU LeuvenCompletedBody Weight | Pregnancy | Health Behavior | First PregnancyBelgium
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Aalborg University HospitalCompleted
-
University of Alabama at BirminghamNational Institute on Minority Health and Health Disparities (NIMHD)Active, not recruitingBody Weight | Adiposity | Infant,PrematureUnited States
-
Ankara UniversityCompletedInflammatory Bowel DiseaseTurkey
-
Rambam Health Care CampusCompletedSmoking Cessation | Muscle Weakness | Body Composition, BeneficialIsrael
-
Universitair Ziekenhuis BrusselTerminatedHIV-1 | Treatment-naïveBelgium